Rallybio Corp (RLYB)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Martin W. MacKay
Employees:
40
234 CHURCH STREET, SUITE 1020, NEW HAVEN, CT 06510
203- 859-3820

Rallybio Corporation engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT)

Data derived from most recent annual or quarterly report
Market Cap 323.257 Million Shares Outstanding38.075 Million Avg 30-day Volume 53.133 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.04
Price to Revenue0.0 Debt to Equity0.0 EBITDA-72.84 Million
Price to Book Value1.4808 Operating Margin0.0 Enterprise Value79.215 Million
Current Ratio23.717 EPS Growth-0.186 Quick Ratio22.116
1 Yr BETA 0.9164 52-week High/Low 15.89 / 4.15 Profit Margin0.0
Operating Cash Flow Growth-31.6531 Altman Z-Score17.5146 Free Cash Flow to Firm -53.737 Million
Earnings Report2023-08-08
View SEC Filings from RLYB instead.

View recent insider trading info

Funds Holding RLYB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RLYB

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-05-22:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-31:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-01:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-28:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-14:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Proposed Sales (Form 144)

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HUNT RONALD

    • Director
    0 2023-05-17 2

    HOPFNER ROBERT LORNE

    • Director
    0 2023-05-17 1

    NASH CHRISTINE A

    • Director
    0 2023-05-17 1

    BOUDREAU HELEN M

    • Director
    0 2023-05-17 1

    PARMAR KUSH

    • Director
    0 2023-05-17 3

    SOTEROPOULOS PAULA

    • Director
    0 2023-05-17 1

    LIU HUI

    • Director
    0 2023-05-17 2

    CHUNG WENDY

    • Director
    0 2023-05-17 4

    LIEBER JONATHAN I SEE REMARKS

    • Officer
    5,000 2023-03-14 3

    5AM PARTNERS V, LLC

    SCHWAB ANDREW J.

    5AM VENTURES V, L.P.

    ROCKLAGE SCOTT M

    • 10% Owner
    3,630,724 2023-03-07 1

    UDEN STEPHEN SEE REMARKS

    • Officer
    0 2023-02-06 1

    MACKAY MARTIN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    0 2023-02-06 1

    RYDER STEVEN CHIEF MEDICAL OFFICER

    • Officer
    0 2023-02-06 1

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PARENT GP LLC

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • 10% Owner
    3,333,388 2022-11-15 1

    5AM OPPORTUNITIES I, L.P.

    SCHWAB ANDREW J.

    5AM OPPORTUNITIES I (GP), LLC

    5AM PARTNERS V, LLC

    5AM VENTURES V, L.P.

    ROCKLAGE SCOTT M

    • 10% Owner
    3,730,724 2022-06-03 1

    FRYER JEFFREY M SEE REMARKS

    • Officer
    723,525 2022-03-21 0

    SHANNON TIMOTHY M

    • Director
    6,041 2022-01-03 0

    FMR LLC

    • SEE REMARK 1
    1,694,388 2021-08-02 0

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    • 10% Owner
    0 2021-07-29 1

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • 10% Owner
    4,194,777 2021-07-29 1

    IANCOVICI LUCIAN

    • Director
    0 2021-07-29 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    CHUNG WENDY - Director

    2023-05-19 17:19:54 -0400 2023-05-17 A 12,353 a 12,353 direct

    LIU HUI - Director

    2023-05-19 17:22:31 -0400 2023-05-17 A 15,490 a 15,490 direct

    HUNT RONALD - Director

    2023-05-19 17:22:07 -0400 2023-05-17 A 15,490 a 15,490 direct

    NASH CHRISTINE A - Director

    2023-05-19 17:25:43 -0400 2023-05-17 A 15,490 a 15,490 direct

    BOUDREAU HELEN M - Director

    2023-05-19 17:25:11 -0400 2023-05-17 A 15,490 a 15,490 direct

    HOPFNER ROBERT LORNE - Director

    2023-05-19 17:24:39 -0400 2023-05-17 A 15,490 a 15,490 direct

    PARMAR KUSH - Director

    2023-05-19 17:26:16 -0400 2023-05-17 A 15,490 a 15,490 direct

    SOTEROPOULOS PAULA - Director

    2023-05-19 17:24:19 -0400 2023-05-17 A 15,490 a 15,490 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    RALLYBIO CORP RLYB 2023-06-06 22:15:03 UTC 4.1993 0.8707 400000
    RALLYBIO CORP RLYB 2023-06-06 21:45:05 UTC 4.1993 0.8707 400000
    RALLYBIO CORP RLYB 2023-06-06 21:15:04 UTC 4.1775 0.8925 400000
    RALLYBIO CORP RLYB 2023-06-06 20:45:04 UTC 4.1775 0.8925 400000
    RALLYBIO CORP RLYB 2023-06-06 20:15:04 UTC 4.1775 0.8925 400000
    RALLYBIO CORP RLYB 2023-06-06 19:45:04 UTC 4.1775 0.8925 400000
    RALLYBIO CORP RLYB 2023-06-06 19:15:03 UTC 4.1775 0.8925 400000
    RALLYBIO CORP RLYB 2023-06-06 18:45:04 UTC 4.1652 0.9048 400000
    RALLYBIO CORP RLYB 2023-06-06 18:15:04 UTC 4.1652 0.9048 400000
    RALLYBIO CORP RLYB 2023-06-06 17:45:04 UTC 4.1652 0.9048 400000
    RALLYBIO CORP RLYB 2023-06-06 17:15:04 UTC 4.1652 0.9048 400000
    RALLYBIO CORP RLYB 2023-06-06 16:45:04 UTC 4.1552 0.9048 400000
    RALLYBIO CORP RLYB 2023-06-06 16:15:03 UTC 4.1552 0.9048 400000
    RALLYBIO CORP RLYB 2023-06-06 15:45:04 UTC 4.1552 0.9048 400000
    RALLYBIO CORP RLYB 2023-06-06 15:15:04 UTC 4.1552 0.9048 400000
    RALLYBIO CORP RLYB 2023-06-06 14:45:04 UTC 4.1988 0.8612 400000
    RALLYBIO CORP RLYB 2023-06-06 14:15:03 UTC 4.1988 0.8612 400000
    RALLYBIO CORP RLYB 2023-06-06 13:45:03 UTC 4.1988 0.8612 400000
    RALLYBIO CORP RLYB 2023-06-06 13:15:03 UTC 4.1988 0.8612 400000
    RALLYBIO CORP RLYB 2023-06-06 12:45:05 UTC 4.1988 0.8612 400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund RLYB -200.0 shares, $-1142.0 2023-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments